Trials / Terminated

TerminatedNCT01430429

Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody

An Open Label Single Arm Study to Investigate the Safety and Efficacy of Multiple Administrations of NI-0801, a Fully Human Anti-CXCL10 Monoclonal Antibody in PBC Patients With an Incomplete Response to Ursodeoxycholic Acid

Status: Terminated
Phase: Phase 2
Study type: Interventional
Enrollment: —

Sponsor: Light Chain Bioscience - Novimmune SA · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The purpose of the study is to assess safety and efficacy of multiple doses of NI-0801 in primary biliary cirrhosis patients with an inadequate response to ursodeoxycholic acid.

Conditions

Primary Biliary Cirrhosis

Interventions

Type	Name	Description
DRUG	NI-0801

Timeline

First posted: 2011-09-08
Last updated: 2014-04-04

Locations

2 sites across 2 countries: Italy, United Kingdom

Source: ClinicalTrials.gov record NCT01430429. Inclusion in this directory is not an endorsement.